US2015335712A1PendingUtilityA1

Treatment of Diseases and Conditions Caused by Increased Vascular Permeability

58
Assignee: STEMNION INCPriority: May 21, 2014Filed: May 20, 2015Published: Nov 26, 2015
Est. expiryMay 21, 2034(~7.8 yrs left)· nominal 20-yr term from priority
Inventors:Larry R. BrownRichard A. BanasHoward C. WesselElise M. Gill
A61K 38/18A61K 35/50A61K 38/19A61K 38/57A61K 38/1866A61K 38/1891A61K 38/1858A61K 38/191
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating diseases and conditions caused by increased vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a CFS composition. 
     
     
         2 . The method of  claim 1  wherein the CFS composition is ACCS. 
     
     
         3 . The method of  claim 2  wherein the CFS composition, including ACCS, is formulated for topical or intranasal administration. 
     
     
         4 . The method of  claim 2  wherein the CFS composition, including ACCS, is formulated for parenteral administration. 
     
     
         5 . The method of  claim 2  wherein the CFS composition, including ACCS, is formulated for enteral administration. 
     
     
         6 . A method for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a CFS composition. 
     
     
         7 . The method of  claim 6  wherein the CFS composition is ACCS. 
     
     
         8 . The method of  claim 7  wherein the CFS composition, including ACCS, is formulated for topical or intranasal administration. 
     
     
         9 . The method of  claim 7  wherein the CFS composition, including ACCS, is formulated for parenteral administration. 
     
     
         10 . The method of  claim 7  wherein the CFS composition, including ACCS, is formulated for enteral administration. 
     
     
         11 . A method for treating viral hemorrhagic fever in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a CFS composition. 
     
     
         12 . The method of  claim 11  wherein the CFS composition is ACCS. 
     
     
         13 . The method of  claim 12  wherein the CFS composition, including ACCS, is formulated for topical or intranasal administration. 
     
     
         14 . The method of  claim 12  wherein the CFS composition, including ACCS, is formulated for parenteral administration. 
     
     
         15 . The method of  claim 12  wherein the CFS composition, including ACCS, is formulated for enteral administration.

Join the waitlist — get patent alerts

Track US2015335712A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.